GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Ryght AI tackles these hurdles with its AI Site Twin platform
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The companies aim to expand treatment options for millions living with metabolic disorders
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated
